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Introduction
The first thrombocytopenic purpura (TP) case fol-
lowing measles vaccination was reported in 1965,1
and that following measles-mumps-rubella (MMR)
vaccination was reported in 1983.2 An active post-
marketing surveillance in 1995 found evidence of in-
creased risk of TP 15–35 days following vaccination.3
The first causal association between MMR vaccination
and TP was reported in 2001.4 More vaccine safety
surveillance studies of TP following MMR vaccination
in France, USA and Canada were published in 1996
and 2003.5–7
Most reports of post-vaccination TP are after
measles-containing vaccine.8 Reports of hematological
adverse events following diphtheria-tetanus-pertussis
(DTP) vaccination are rare. Only 1 report of 3 cases
of acute hemolytic anemia in 1978,9 and 1 report of
TP in 1993 have been published.10 Several reports of
TP following hepatitis B virus (HBV) vaccination have
been published since 1994, when active HBV vacci-
nation was introduced worldwide.11–16 One report of
J Chin Med Assoc • December 2010 • Vol 73 • No 12634
ORIGINAL ARTICLE
Thrombocytopenic Purpura Following 
Vaccination in Early Childhood: Experience of 
a Medical Center in the Past 2 Decades
Yuh-Lin Hsieh1, Lung-Huang Lin1,2*
1Department of Pediatrics, Cathay General Hospital, and 2College of Medicine, 
Fu-Jen Catholic University, Taipei, Taiwan, R.O.C.
Background: The etiology of thrombocytopenia during infancy and early childhood may be different from that of older
children, because young children frequently receive vaccines. The following study was performed to understand whether
there was a causal relationship between vaccinations and thrombocytopenia.
Methods: We retrospectively studied, through chart review, the relationship between vaccination and thrombocytopenic
purpura in 20 children with thrombocytopenia (platelet count < 150 × 103/mm3) under the age of 3 years who were hos-
pitalized between 1989 and 2010. Cases with a history of infectious symptoms/signs between vaccination and the
occurrence of thrombocytopenia were excluded. Thrombocytopenia cases not diagnosed as idiopathic thrombocytopenic
purpura but as post-vaccination thrombocytopenic purpura should have a similar vaccination-to-thrombocytopenia interval
as reported in Western journals, but which should not be more than 9 weeks after vaccination.
Results: Of the 20 cases of thrombocytopenic purpura, 12 followed vaccination and 8 were considered idiopathic. Of the
12 post-vaccination cases, 5 occurred after the second dose of hepatitis B virus vaccine at 1 month of age, 4 occurred
after the first dose of diphtheria-tetanus-acellular pertussis-containing vaccine at 2–3 months of age, 2 occurred after
the first dose of measles-mumps-rubella vaccine at 16 months of age, and 1 occurred after the first dose of varicella
vaccine at 14 months of age. One of these 12 cases, who also had a marked decrease in hemoglobin level without
bleeding, was suspected to have Evans syndrome.
Conclusion: Vaccination may be a risk factor for infant thrombocytopenic purpura. [J Chin Med Assoc 2010;73(12):
634–637]
Key Words: anemia, thrombocytopenia, vaccination
© 2010 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
*Correspondence to: Dr Lung-Huang Lin, Department of Pediatrics, Cathay General Hospital, 280,
Section 4, Jen-Ai Road, Taipei 106, Taiwan, R.O.C.
E-mail: sasuan.sara@msa.hinet.net ● Received: June 23, 2010 ● Accepted: September 14, 2010
Evans syndrome following recombinant HBV vacci-
nation was described in an adult in 1992.16
Here, we report 12 children under the age of 
3 years who developed post-vaccination TP during
the past 2 decades in our hospital.
Methods
Through chart review, we retrospectively examined
20 TP children under the age of 3 years, who were
hospitalized between 1989 and 2010, to search for a
relationship between vaccination and TP or the cause
of TP. Cases with a history of infectious symptoms/
signs between vaccination and the occurrence of throm-
bocytopenia were excluded. Thrombocytopenia was
defined as having a platelet count < 150 × 103/mm3.
Anemia was defined as having a hemoglobin level < 2
standard deviations of the normal level for age. Throm-
bocytopenia cases not diagnosed as idiopathic TP
(ITP) but as post-vaccination TP should have a similar
vaccination-to-thrombocytopenia interval as reported
in Western journals, but which should not be more
than 9 weeks after vaccination.
Results
Twelve of the 20 TP cases were considered to be post-
vaccination TP while 8 were not. The mean platelet
count of the post-vaccination cases was 8 × 103/mm3
(range, 1–19×103/mm3). The mean intervals between
vaccination and TP were: 18 days (range, 6–34 days)
following HBV vaccination; 16 days (range, 5–23
days) following acellular DTP (DTaP)-containing vac-
cination; 1 month following MMR vaccination; and 
9 weeks following varicella vaccination.
Six of the 12 post-vaccination cases had received
combined-component vaccines, including 4 cases fol-
lowing DTaP-containing vaccine that occurred before
3.5 months of age, and 2 cases after MMR vaccine at
16 months of age. The other 6 cases received single-
component vaccines, including 5 cases after HBV vac-
cine at 1 month of age, and 1 case after varicella vaccine
at 14 months of age.
Among these 12 cases, 1 also had a marked decrease
in hemoglobin, but without bleeding. The hemoglo-
bin dropped from 10 g/dL to 8 g/dL in 1 day, with
normal stool routine, increased reticulocyte count to
3%, decreased haptoglobin to 36.4 mg/dL, and hemo-
lytic pattern peripheral blood smear. This patient was
suspected to have Evans syndrome, and TP occurred
after the second dose of HBV vaccination at 1 month
and 19 days of age. Four cases had their hemoglobin
drop to a mean of 7 g/dL (range, 5.8–8.0 g/dL); they
had stool occult blood without gross tarry stool,
bloody stool, or gastrointestinal symptoms.
Eleven of the post-vaccination TP cases were treated
with intravenous immunoglobulin (IVIG) 2g/kg over
a period of 2–4 days; the remaining case was treated
with steroid. All 12 cases recovered within 4 days
(range, 1–6 days) without recurrence, even after receiv-
ing the same vaccination later on. All of the informa-
tion above is summarized in Table 1.
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Table 1. Patient characteristics, biological data, treatment and outcome
Case Age Vaccination date
Vaccine 
TP onset date
Platelet count Hb TP 
Treatment Recurrence
type (´ 103/mm3) (g/dL) duration
1 1 mo 18 d Aug 31, 1989 2nd HBV Sep 16, 1989 3 7.4 4 d IVIG No
2 2 mo 6 d Jun 6, 1990 2nd HBV Jun 25, 1990 10 5.8 6 d IVIG No
3 2 mo 7 d Jun 13, 1995 2nd HBV Jul 17, 1995 1 7.0 1 d Steroid No
4 1 mo 26 d May 27, 1996 2nd HBV Jun 12, 1996 8 10.0 6 d IVIG No
5 1 mo 19 d Mar 25, 2006 2nd HBV Mar 31, 2006 3 8.0 5 d IVIG No
6 2 mo 26 d May 8, 2001 2nd HBV Aug 4, 2001 8 9.0 1.5 d IVIG No
1st 3-in-1
7 3 mo Apr 9, 2005 1st 5-in-1 May 2, 2005 5 8.9 5 d IVIG No
8 2 mo 9 d Jun 17, 2006 1st 5-in-1 Jun 23, 2006 5 8.9 3 d IVIG No
9 3 mo 2 d Dec 10, 2007 2nd 6-in-1 Dec 15, 2007 2 8.0 6 d IVIG No
10 1 yr 4 mo Oct 20, 1997 1st MMR Nov 20, 1997 18 12.7 2 d IVIG No
11 1 yr 4 mo Aug 6, 2002 1st MMR Sep 6, 2002 19 10.5 2 d IVIG No
12 1 yr 2.5 mo Feb 11, 2006 1st varicella Apr 15, 2006 18 11.8 6 d IVIG No
TP = thrombocytopenic purpura; Hb = hemoglobin; HBV = hepatitis B virus vaccination; IVIG = intravenous immunoglobulin; 3-in-1 = diphtheria-tetanus-acellular
pertussis-containing vaccine; 5-in-1 = 3-in-1 + Haemophilus influenzae type b + inactive polio virus; 6-in-1 = 5-in-1 + HBV; MMR = measles-mumps-rubella 
vaccination.
Of the 8 ITP cases, all had a history of recovery
from recent virus infection such as upper respiratory
tract infection.
Discussion
In Taiwan, the current vaccination policy is: 3 doses
of HBV vaccine, which are given in the first 5 days
after birth, then at 1 month and finally at 6 months; 
4 doses of DTaP-containing vaccine, which are given
at 2, 4, 6 and 18 months; varicella vaccine, which is
given at 1 year; and MMR vaccine, which is given at
15 months. Whole-cell DTP vaccine (trivalent) has been
imported since 1954, DTaP (trivalent) since 1998,
DTaP-Haemophilus influenzae type b (Hib)-inactive
polio virus (pentavalent) since 2002, and pentavalent-
HBV (hexavalent) since 2005.
In this study, the first dose of trivalent or pentava-
lent vaccine before 3 months of age resulted in TP,
while the second, third and fourth doses at 4, 6 and
18 months did not. In addition, the second dose of
hexavalent vaccine at 3 months resulted in TP. There-
fore, rather than considering whether it is the first or
second dose of a vaccine, we suspect that infants older
than 4 months of age will not have TP after receiving
DTaP-containing vaccination. Because TP following
Hib vaccine or inactive polio vaccine has not been
reported, but TP has been reported after DTaP vac-
cine, we suspect that the DTaP component in pen-
tavalent vaccine will lead to TP.10
The interval between vaccination and TP in this
study is the same as that reported by others, especially
the longer interval between measles-containing vaccine
and TP. But the interval between varicella vaccine and
TP was 9 weeks in our study, although it was only 
6 weeks in other reports.7,8,17–20 This difference needs
large-scale case study in Taiwan to verify whether our
case was of ITP or post-varicella vaccine TP.
Two of the ITP cases had received MMR or measles
vaccine 1.5 months previously and had had upper 
respiratory tract infection 10 days before TP. Western
investigators have reported that TP occurs within 
1 month following measles-containing vaccination.
As for our 2 cases, 1.5 months is a rather long interval
to correlate with vaccination, so we assumed that they
were not of post-vaccination TP.
Three TP cases following DTaP-containing vacci-
nation were with pentavalent or hexavalent vaccines
between mid-2005 and the end of 2007; the other
case was after DTaP vaccination in 2001. There was
no case between 2001 and 2005. Four TP cases fol-
lowing HBV vaccination occurred between 1989 and
1996, and 1 case occurred in 2006. There were no
cases between 1996 and 2006. So, in this study, there
were clustered occurrences over specific years for DTaP-
containing or HBV vaccines. These findings need fur-
ther large-scale country-wide review to clarify their
significance. Two cases of TP before 1992 occurred
following plasma-derived HBV vaccination in this
study. But no other TP case following plasma-derived
HBV vaccination has previously been reported.14 No
TP following Japanese B encephalitis vaccination, oral
polio vaccination, or rotavirus vaccination was found
in our study. TP following influenza or pneumococcus
vaccination has been reported by other investigators,
but did not occur in this study.7,21
The most frequent cause of post-vaccination TP in
this study was HBV vaccination, followed by DTaP,
and then MMR. However, in Western reports, MMR
vaccination was the most frequent cause, followed by
DTP and then HBV.7
There is discussion on whether or not such 
severe thrombocytopenia after vaccination is immune-
mediated.22 Although childhood ITP has an 85% recov-
ery rate, it will sometimes relapse months or years later.
All of our post-vaccination TP cases recovered and did
not experience recurrence even after the same vacci-
nation months later. Post-vaccination TP has the same
clinical picture and treatment options as ITP. The first-
line treatment option for ITP is usually steroids. How-
ever, all except 1 of our post-vaccination TP cases were
treated with IVIG to avoid any steroid-related com-
plication in infants. The usual timing of further vacci-
nation after previous IVIG treatment is 6 months
later. But our pediatricians sometimes administer fur-
ther vaccinations earlier than that, resulting in reduced
antibody production. So, from this study, our treat-
ment suggestion for post-vaccination TP is short-term
steroids, on the basis of there being no recurrence
and benign course in our cases, to avoid further vacci-
nation delay.
Through several types of laboratory tests, including
red blood cell morphology of peripheral blood smear,
reticulocyte count and haptoglobin, we suspected that
the patient who had anemia had immune hemolytic
anemia. We did not perform further detailed labora-
tory examinations to prove this because it is not prac-
tical to draw more blood from such a small baby, and
it is not easy to prove autoimmune hemolytic anemia
without detailed tests.9,23 So, this case was only sus-
pected to be Evans syndrome following HBV vacci-
nation, and different from Western reports following
DTP vaccination in adults. It is possible that the im-
practicality of drawing a sufficient amount of blood
for unequivocal diagnosis is the reason for why there
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is no report of Evans syndrome following vaccination
in infants and children.16
Because of the limited case number in our study, 
a country-wide large-scale retrospective review of the
issues examined in this report, and prospective studies
to compare the pros and cons of treatment with steroids
or IVIG, should be conducted.
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